CANCER AND LEUKEMIA GROUP B

这是临床继续研究的续期申请。 癌症作为CALGB的成员。康奈尔大学纽约医院 医疗中心与北岸大学医院和 附属机构仍然是该基金的主要贡献者 CALGB的科学、临床和管理活动。我们的 多学科发展反映在我们的临床活动(我们的 集团现在是CALGB研究的主要贡献者)和我们的 参与CALGB事务。领导力活动是 反映在我们的行政和科学贡献中 CALGB，我们的多学科增长，以及我们的试点和第二阶段 程序。 我们的目标是以合作的方式参与 癌症治疗试验的设计和实施。在此背景下 我们将(1)确定缓解的效果、程度和持续时间 以及对所关注的疾病的治疗的其他反应 CALGB，(2)研究自然历史，免疫学方面， 所研究的疾病的细胞遗传学和分子生物学 CALGB，(3)参与试点、第二阶段和多学科 CALGB试验，(4)继续高水平的患者收益和 收集最近拨款年度的数据，(5)继续 积极参与小组活动，因为这与小组有关 科学与团体管理。

This is a renewal application for continuing research in clinical cancer as a member of CALGB. The New York Hospital - Cornell Medical Center together with North Shore University Hospital and affiliated institutions remain a major contributor to the scientific, clinical and administrative activities of CALGB. Our multidisciplinary growth is reflected in our clinical activities (our group is now the leading contributor to CALGB studies) and our participation in CALGB affairs. Leadership activities are reflected in our administrative and scientific contributions to CALGB, our multidisciplinary growth, and in our pilot and phase II programs. Our aims are to participate in a cooperative approach in the design and conduct of therapeutic trials in cancer. In this context we will (1) determine the effect, extent and duration of remission and other responses to treatment of the diseases of concern to CALGB, (2) study the natural history, immunologic aspects, cytogenetics, and molecular biology of the diseases investigated by CALGB, (3) participate in pilot, phase II and multidisciplinary trials of CALGB, (4) continue the high level of patient accrual and data collection of the recent grant years, (5) continue our vigorous participation in Group activities as it pertains to Group science and Group administration.